Stub Trine, Kristoffersen Agnete E, Overvåg Grete, Jong Miek C, Musial Frauke, Liu Jianping
The National Research Center in Complementary and Alternative Medicine (NAFKAM) Department of Community Medicine, Faculty of Health Science, UiT, The Arctic University of Norway, 9037 Tromsø, Norway.
The National Research Center in Complementary and Alternative Medicine (NAFKAM) Department of Community Medicine, Faculty of Health Science, UiT, The Arctic University of Norway, 9037 Tromsø, Norway; Science and Health Library, UiT The Arctic University of Norway, Hansine Hansens veg 19, 9019 Tromsø, Norway; Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine and Pharmacology, Beijing, China.
Explore (NY). 2022 Jan-Feb;18(1):114-128. doi: 10.1016/j.explore.2020.11.008. Epub 2020 Nov 28.
Almost all health care interventions have the potential to be associated with risk to patient safety. Different terminologies are used to define treatment induced risk to patient safety and a common definition is the term adverse effect. Beyond the concept of adverse effect and specific to homeopathy is the concept of homeopathic aggravation. Homeopathic aggravation describes a transient worsening of the patients' symptoms, which is not understood as an adverse effect. In order to ensure patient safety within a homeopathic treatment setting, it is important to identify adverse effects, as well as homeopathic aggravations, even though it may be challenging to distinguish between these two concepts. To date there is an obvious lack of systematic information on how adverse effects and homeopathic aggravations are reported in studies. This systematic review and meta-analysis focuses on observational studies, as a substantial amount of the research base for homeopathy are observational.
Eight electronic databases, central webpages and journals were searched for eligible studies. The searches were limited from the year 1995 to January 2020. The filters used were observational studies, human, English and German language. Adverse effects and homeopathic aggravations were identified and graded according to The Common Terminology Criteria for Adverse Effects (CTCAE). Meta-analysis was performed separately for adverse effects and homeopathic aggravations.
A total of 1,169 studies were identified, 41 were included in this review. Eighteen studies were included in a meta-analysis that made an overall comparison between homeopathy and control (conventional medicine and herbs). Eighty-seven percent (n = 35) of the studies reported adverse effects. They were graded as CTCAE 1, 2 or 3 and equally distributed between the intervention and control groups. Homeopathic aggravations were reported in 22,5% (n = 9) of the studies and graded as CTCAE 1 or 2. The frequency of adverse effects for control versus homeopathy was statistically significant (P < 0.0001). Analysis of sub-groups indicated that, compared to homeopathy, the number of adverse effects was significantly higher for conventional medicine (P = 0.0001), as well as other complementary therapies (P = 0.05).
Adverse effects of homeopathic remedies are consistently reported in observational studies, while homeopathic aggravations are less documented. This meta-analysis revealed that the proportion of patients experiencing adverse effects was significantly higher when receiving conventional medicine and herbs, compared to patients receiving homeopathy. Nonetheless, the development and implementation of a standardized reporting system of adverse effects in homeopathic studies is warranted in order to facilitate future risk assessments.
几乎所有医疗保健干预措施都有可能对患者安全构成风险。用于定义治疗对患者安全造成的风险的术语各不相同,一个常用的定义是“不良反应”。除了不良反应的概念之外,顺势疗法特有的概念是顺势疗法加重反应。顺势疗法加重反应描述的是患者症状的短暂恶化,这并不被视为不良反应。为了在顺势疗法治疗环境中确保患者安全,识别不良反应以及顺势疗法加重反应非常重要,尽管区分这两个概念可能具有挑战性。迄今为止,关于研究中如何报告不良反应和顺势疗法加重反应明显缺乏系统信息。本系统评价和荟萃分析聚焦于观察性研究,因为顺势疗法的大量研究基础都是观察性的。
在八个电子数据库、中心网页和期刊中搜索符合条件的研究。搜索范围限制在1995年至2020年1月。使用的筛选条件为观察性研究、人类、英语和德语。根据《不良反应通用术语标准》(CTCAE)识别并分级不良反应和顺势疗法加重反应。分别对不良反应和顺势疗法加重反应进行荟萃分析。
共识别出1169项研究,本评价纳入了41项。18项研究纳入了一项对顺势疗法与对照(传统医学和草药)进行总体比较的荟萃分析。87%(n = 35)的研究报告了不良反应。这些不良反应被分级为CTCAE 1、2或3级,在干预组和对照组中分布均匀。22.5%(n = 9)的研究报告了顺势疗法加重反应,并分级为CTCAE 1或2级。对照与顺势疗法的不良反应发生率在统计学上具有显著差异(P < 0.0001)。亚组分析表明,与顺势疗法相比,传统医学(P = 0.0001)以及其他补充疗法(P = 0.05)的不良反应数量显著更高。
观察性研究中一致报告了顺势疗法药物的不良反应,而顺势疗法加重反应的记录较少。这项荟萃分析表明,与接受顺势疗法的患者相比,接受传统医学和草药治疗的患者出现不良反应的比例显著更高。尽管如此,为了便于未来的风险评估,仍有必要制定并实施顺势疗法研究中不良反应的标准化报告系统。